Picture EBD Group BIO-Europe Spring 2021 Digital 650x80
Organisation › Details

Genticel S.A. (Euronext Paris + Brussels: GTCL)

GENTICEL is a clinical stage biopharmaceutical company based in Paris and Toulouse, France, which develops vaccines for patients infected with Human Papillomavirus (HPV). Besides ProCervix, its other pipeline products include CyaA-based multivalent HPV vaccines with additional virus subtype coverage. *


Period Start 2010-03-09 renamed
Period End 2017-02-28 renamed
  Group Genkyotex (Group)
  Today Genkyotex S.A. (Euronext Paris + Brussels: GKTX)
  Predecessor BT Pharma S.A.
  Successor Genkyotex S.A. (Euronext Paris + Brussels: GKTX)
Products Industry therapeutic vaccine
  Industry 2 GTL001 (ProCervix)
Persons Person Timmerman, Benedikt (Genticel 201304 CEO + Founder)
  Person 2 Koch, Martin (Genticel 201507– interim CEO before CFO)
Region Region Toulouse
  Country France
  Street 515 rue Pierre et Marie Curie
BP 28262
  City 31682 Labège – Innopole Cedex
  Tel +33-5-6128-7060
    Address record changed: 2020-12-02
Basic data Employees n. a.
  Currency EUR
  Annual sales 13,104,060 (income, total (2016) 2016-12-31)
  Profit -7,240,271 (2016-12-31)
  Cash 4,663,013 (2016-12-31)
    * Document for �About Section�: 
Record changed: 2019-06-09


Picture Kentro Design Corporate and Web Design Berlin 650x65px

More documents for Genkyotex (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture Berlin Partner Life Sciences Report 2019/2020 Brandenburg 650x80px

» top